EUVIMEDEUVIMED entdecken
Crossref

The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study

William R Zhang iD, Tina Bhutani, Jeffrey P North iD

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.14729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2025. Verfasst von William R Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-1. Die Arbeit nennt 25 Literaturangaben. Gefördert von: UCSF Clinical and Translational Science Training Resident Research Funding Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.

Methods

Retrospective immunohistochemical and chart review pilot study.

Results

Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).

Conclusions

Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-1HumansPilot ProjectsMaleFemaleRetrospective StudiesMiddle AgedAdultImmunohistochemistryAgedBiological TherapyBiomarkersInterleukin-23

Stichwörter der Autor:innen

biologicimmunohistochemical staininginterleukin‐36 (IL‐36)psoriasistreatment response

Substanzen

Interleukin-1interleukin 36, humanBiomarkersInterleukin-23

Autor:innen und Institutionen

  • Department of Dermatology, University of California, San Francisco, California, USA.
  • Department of Pathology, University of California, San Francisco, California, USA.

ORCID-Profile: William R Zhang, Jeffrey P North

Förderung

  • UCSF Clinical and Translational Science Training Resident Research Funding Program

Zitieren

APA

Zhang, W. R., Bhutani, T., & North, J. P. (2025). The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14729

Vancouver

Zhang WR, Bhutani T, North JP. The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14729

BibTeX
@article{Zhang2025,
  author = {Zhang, William R and Bhutani, Tina and North, Jeffrey P},
  title = {The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.14729}
}
Kostenlos starten →